| Document |
Document Title |
|
WO/2020/214835A1 |
Provided are methods for producing levulinic acid from hemp hurds. In some embodiments, the methods include dissolving hemp hurds in an ionic liquid medium to produce a cellulose-rich product; hydrolyzing cellulose present in the cellulo...
|
|
WO/2020/208594A1 |
The present invention provides various solid state forms of elafibranor. In an aspect of present invention provides a stable amorphous form of elafibranor and its processes. The present invention also provides a stable admixture form of ...
|
|
WO/2020/200952A1 |
The present invention pertains to a process for preparing 3-hydroxy-3-methylbutyrate (HMB) or a salt thereof, the method comprising (a) reacting isobutylene oxide with cyanide in order to obtain 3- hydroxy-3-methylbutyronitrile, and (b) ...
|
|
WO/2020/206448A1 |
Provided are methods of using compounds, pharmaceutical compositions, cosmetic and dermatological compositions or nutritional supplement compositions, comprising omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFAs) and/or ...
|
|
WO/2020/194152A1 |
Aspect of the present application provides cost effective and commercially viable process for preparation of Bempedoic acid. The process involves the reduction of compound formula I to obtain compound formula II which is hydrolyzed to ge...
|
|
WO/2020/193681A1 |
The present invention relates to derivatives of 10-methylene lipids, their preparation and their use.
|
|
WO/2020/184054A1 |
The present invention provides a (meth)acrylic-acid-metal-salt-containing composition that has exceptional solubility/dispersibility (preferably solubility) in low-polarity media and that resists bleed out of the metal salt. The present ...
|
|
WO/2020/173961A1 |
The invention relates to a method for degradation of plastic materials into terephthalic acid (TPA)and/or ethylene glycol and/or other monomers that form the plastic materials.
|
|
WO/2020/174096A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2020/171039A1 |
This invention addresses the problem of providing a novel fluorene compound, which has a 2,3-benzofluorene skeleton, is highly versatile as a "dicarboxylic acid component" of a resin starting material, has a high refractive index, and is...
|
|
WO/2020/158752A1 |
[Problem] To provide an adsorbent recycling method for regenerating a used adsorbent and allowing purification capability to be exhibited stably in order to maintain constant the composition of a synthetic gas that has been purified usin...
|
|
WO/2020/150568A1 |
Methods for syntheses of organic acids from a-keto acids, including methods for syntheses of isotopically encriched organic acids from a-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabo...
|
|
WO/2020/141419A2 |
The present invention relates to novel pharmaceutically acceptable salts of Bempedoic acid, novel intermediates of Bempedoic acid, novel crystalline form of Bempedoic acid and novel processes for the preparation of Bempedoic acid or its ...
|
|
WO/2020/140309A1 |
The present invention provides a method for preparing a 3-hydroxybutyrate amino acid salt compound, comprising: (1) adding ethyl 3-hydroxybutyrate or methyl 3-hydroxybutyrate into a reaction vessel, taking water as a solvent, adding a ba...
|
|
WO/2020/138902A1 |
The present invention relates to a catalyst compound in which a transition metal is coordinated to a ligand containing two or three chain-like imidazolium or triazolium functional groups, and a method for preparing a formate compound and...
|
|
WO/2020/127243A2 |
The present invention relates to ethoxylate surfactant compounds of general formula (I) A-X-0-[CH2-CH2-0]n-R1, wherein A is a linear C7-C33-alkyl or -alkenyl residue, wherein one of the hydrogen atoms is substituted by residue -O-[CH2-CH...
|
|
WO/2020/126088A1 |
The present invention refers to a co-crystal of Ketoprofen Lysine named Form 1, a pharmaceutical composition comprising said co-crystal, a process for its production and to its use in the treatment of pain and inflammatory diseases.
|
|
WO/2020/123861A1 |
Compounds are provided having the following structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein X1, X2, and R1 are as defined herein. Such compounds function as ...
|
|
WO/2020/113995A1 |
Provided is a method for preparing levulinic acid and furfural by means of the direct liquefaction of a fibrous biomass. The method comprises using the fibrous biomass as a raw material, mixing same with a sulfate catalyst in a polar apr...
|
|
WO/2020/107515A1 |
A method of preparing a 3-hydroxybutyric acid salt, comprising: (1) providing ethyl-3-hydroxybutyrate or methyl-3-hydroxybutyrate, going through alkaline catalyzed hydrolysis, obtaining 3-hydroxybutyric acid; (2) the 3-hydroxybutyric aci...
|
|
WO/2020/112941A2 |
The present disclosure relates to solid state forms of Lumateperone besylate, processes for preparation thereof and pharmaceutical compositions thereof.
|
|
WO/2020/102892A1 |
The present application relates to novel 3'-unsaturated abscisic acid (ABA) derivatives of Formula (I) as ABA antagonists. For example, the present application relates to methods of using compounds of Formula (I) for reducing adverse eff...
|
|
WO/2020/100911A1 |
The present invention provides a production method for efficiently obtaining ferric citrate hydrate which exhibits various BET specific surface areas and a high degree of purity regardless of the starting material which is used. The pres...
|
|
WO/2020/100912A1 |
The present invention provides a production method for easily obtaining highly pure ferric citrate hydrate which exhibits reduced organic and inorganic impurities and has a high BET specific surface area. The present invention is a ferri...
|
|
WO/2020/088510A1 |
The present invention relates to a preparation method for (R)-o-chloromandelic acid. By means of the preparation method, the present invention improves the utilization rate of a reaction buffer, thereby reducing the production cost of (R...
|
|
WO/2020/092906A1 |
Provided herein are co-crystals comprising Compound 1 and a coformer. Pharmaceutical compositions comprising the co-crystals and methods for treating, preventing and managing disease are also disclosed.
|
|
WO/2020/081405A1 |
Compounds and methods related to the prevention and treatment of diseases and conditions, some of which are facilitated by melanogenesis are disclosed. Specifically, the present subject matter includes a series of compounds and compositi...
|
|
WO/2020/080713A1 |
The present invention provides a method for filtering out organic acids, the method effectively recovering a high concentration of organic acids from a low concentration organic acid solution.
|
|
WO/2020/075196A1 |
A novel crystalline forms of (N-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, (S)-malate, pharmaceutical compositions containing said crystalline forms and the use of said crystalline for...
|
|
WO/2020/074964A1 |
The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative ther...
|
|
WO/2020/074852A1 |
Molecular complexes comprising 2-methyl,4-chlorophenoxyacetic acid (MCPA) and a compound selected from the group of triazine herbicides are described, together with compositions comprising such molecular complexes, and methods of their p...
|
|
WO/2020/060823A1 |
A novel salt of treprostinil and methods of its preparation and use are disclosed.
|
|
WO/2020/050339A1 |
Provided is an industrially useful method for manufacturing (1R,2S)-2-{[((2,4-dimethylpyrimidine-5-yl)oxy}methyl]-2-(3-f
luorophenyl)-N-(5-fluoropyridine-2-yl)cyclopropane-1-carboxa
mide. In the present invention, (1R,2S)-2-{[((2,4-dimet...
|
|
WO/2020/050249A1 |
Provided is a method for producing a trifluoropyruvate fluoride dimer, said method comprising a reaction step for reacting hexafluoropropylene oxide with an aldehyde.
|
|
WO/2020/049150A1 |
Herein are provided novel salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolid
in-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxy
late namely the oxalate salt (I) and the dibenzoyltartrate salt (II).
|
|
WO/2020/041871A1 |
This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-β-hydroxybutyl-R-β-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease....
|
|
WO/2020/039297A1 |
The present invention relates to the novel compounds of Formula I, and salts thereof and use of said compounds as intermediates for the preparation of (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-
en-1-yl)phenoxy)-2-methyl...
|
|
WO/2020/038464A1 |
A fibric acid compound, pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, metabolite forms thereof or any combination or mixture thereof; a pharmaceutical composition con...
|
|
WO/2020/037164A1 |
Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
|
|
WO/2020/027150A1 |
A compound represented by general formula (I) (wherein each symbol is as defined in the description) or a salt thereof has a potent neural protecting and/or repairing effect and, therefore, is usable as a therapeutic agent for neurologic...
|
|
WO/2020/020064A1 |
Disclosed in the present invention is a method for safely preparing pimavanserin and a tartrate salt thereof using triphosgene. The synthesis routes comprise (1), (2), (3), (4) and (5). The raw materials used in the method of the present...
|
|
WO/2020/022256A1 |
This alcohol production method for producing an alcohol from a carbonyl compound uses a catalyst in which a metal component containing rhenium having an average valency of 4 or less is supported on a carrier containing zirconium oxide. T...
|
|
WO/2020/016290A1 |
The present invention refers to a process for the purification of levulinic acid, an aqueous solution comprising levulinic acid and a process for the production of levulinic acid.
|
|
WO/2020/016841A1 |
The present invention relates to a novel process for preparing compounds of formula I; (I) from compounds of formula III or compounds of formula XII which in turn are obtained by a novel process according to the present invention, (III) ...
|
|
WO/2020/013330A1 |
The purpose of the present invention is to provide: crystals of a eucomic acid non-solvate which have a low methanol content and excellent flowability; and a method for producing the crystals. The crystals of a eucomic acid non-solvate, ...
|
|
WO/2019/243369A1 |
The present invention relates to compounds of formula (I) that are able to generate oct-2-en-4-one and thus to provide a long-lasting or substantive strawberry odor to the environment. Moreover, the present invention relates to a method ...
|
|
WO/2019/230685A1 |
The present invention addresses the problem of providing a novel crystal of 2,2'-bis(carboxymethoxy)-1,1'-binaphthyl suitable as a resin raw material having excellent optical characteristics. As a solution, it was found that by carrying ...
|
|
WO/2019/227202A1 |
Disclosed are pharmaceutical salts and co-crystals of pentoxifylline, clonidine and linsidomine with caffeic acid, protocatechuic acid or α-lipoic acid, and method for preparing thereof. Also disclosed are topical compositions comprisin...
|
|
WO/2019/230803A1 |
One aspect of the present invention is a method for producing a polyphenol composition from bagasse, which comprises: a step wherein bagasse is pre-treated with use of at least one alkaline solution that is selected from the group consis...
|
|
WO/2019/204148A1 |
Ketogenic compositions including beta-hydroxybutyrate (beta-hydroxybutyrate) and acetoacetate are formulated to induce, promote, or sustain ketosis in a mammal. The combined beta-hydroxybutyrate/acetoacetate compositions include an amoun...
|
